Avenue Therapeutics (ATXI) Competitors $0.84 +0.13 (+18.69%) As of 10/14/2025 10:19 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ATXI vs. KPRX, ALBT, TNFA, GOVX, CELZ, GNPX, HCWB, BCTX, QLGN, and CYCNShould you be buying Avenue Therapeutics stock or one of its competitors? The main competitors of Avenue Therapeutics include Kiora Pharmaceuticals (KPRX), Avalon GloboCare (ALBT), TNF Pharmaceuticals (TNFA), GeoVax Labs (GOVX), Creative Medical Technology (CELZ), Genprex (GNPX), HCW Biologics (HCWB), Briacell Therap (BCTX), Qualigen Therapeutics (QLGN), and Cyclerion Therapeutics (CYCN). These companies are all part of the "pharmaceutical products" industry. Avenue Therapeutics vs. Its Competitors Kiora Pharmaceuticals Avalon GloboCare TNF Pharmaceuticals GeoVax Labs Creative Medical Technology Genprex HCW Biologics Briacell Therap Qualigen Therapeutics Cyclerion Therapeutics Avenue Therapeutics (NASDAQ:ATXI) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations. Do insiders and institutionals have more ownership in ATXI or KPRX? 17.3% of Avenue Therapeutics shares are owned by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. 1.8% of Avenue Therapeutics shares are owned by company insiders. Comparatively, 0.1% of Kiora Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has stronger valuation & earnings, ATXI or KPRX? Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than Avenue Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvenue TherapeuticsN/AN/A-$10.38M-$0.95-0.89Kiora PharmaceuticalsN/AN/A$3.60M-$2.91-0.94 Does the media refer more to ATXI or KPRX? In the previous week, Kiora Pharmaceuticals had 1 more articles in the media than Avenue Therapeutics. MarketBeat recorded 2 mentions for Kiora Pharmaceuticals and 1 mentions for Avenue Therapeutics. Kiora Pharmaceuticals' average media sentiment score of 0.95 beat Avenue Therapeutics' score of 0.00 indicating that Kiora Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Avenue Therapeutics Neutral Kiora Pharmaceuticals Positive Which has more risk and volatility, ATXI or KPRX? Avenue Therapeutics has a beta of 0.04, meaning that its share price is 96% less volatile than the S&P 500. Comparatively, Kiora Pharmaceuticals has a beta of -0.67, meaning that its share price is 167% less volatile than the S&P 500. Do analysts recommend ATXI or KPRX? Kiora Pharmaceuticals has a consensus price target of $10.00, indicating a potential upside of 264.96%. Given Kiora Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Kiora Pharmaceuticals is more favorable than Avenue Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avenue Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Kiora Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is ATXI or KPRX more profitable? Kiora Pharmaceuticals' return on equity of -47.17% beat Avenue Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Avenue TherapeuticsN/A -471.57% -296.50% Kiora Pharmaceuticals N/A -47.17%-34.00% SummaryKiora Pharmaceuticals beats Avenue Therapeutics on 9 of the 13 factors compared between the two stocks. Get Avenue Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATXI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATXI vs. The Competition Export to ExcelMetricAvenue TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.26M$1.03B$6.05B$10.52BDividend YieldN/A4.84%5.73%4.80%P/E Ratio0.051.3085.0427.24Price / SalesN/A186.07571.88227.55Price / CashN/A17.6437.5761.53Price / Book0.447.7012.676.74Net Income-$10.38M-$7.59M$3.32B$276.59M7 Day Performance12.67%1.59%-1.35%-0.47%1 Month Performance0.87%28.44%8.09%7.47%1 Year Performance-59.67%-8.89%78.89%34.58% Avenue Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATXIAvenue Therapeutics2.0507 of 5 stars$0.84+18.7%N/A-58.4%$2.26MN/A0.054News CoverageKPRXKiora Pharmaceuticals3.2997 of 5 stars$2.73-0.4%$10.00+266.3%-11.6%$9.36M$16.02M-0.9410Positive NewsALBTAvalon GloboCare1.8492 of 5 stars$2.39+2.1%N/A-30.6%$9.18M$1.33M-0.125TNFATNF Pharmaceuticals0.0523 of 5 stars$4.90-14.8%N/A-97.6%$9.05MN/A-0.026Negative NewsGap DownGOVXGeoVax Labs2.8036 of 5 stars$0.55-3.9%$8.50+1,438.2%-69.9%$8.80M$6.14M-0.2710CELZCreative Medical Technology1.4202 of 5 stars$3.41+0.9%N/A-23.6%$8.80M$6K-1.075Analyst ForecastGNPXGenprex1.1512 of 5 stars$0.20-1.0%N/A-26.1%$8.68MN/A0.0020News CoverageNegative NewsHCWBHCW Biologics1.6451 of 5 stars$4.03flat$35.00+768.5%-78.7%$8.66M$2.57M-0.2940BCTXBriacell Therap2.3093 of 5 stars$12.63-4.5%$320.00+2,433.7%-91.5%$8.59MN/A-0.158QLGNQualigen TherapeuticsN/A$5.03flatN/A-54.8%$8.53MN/A0.0050CYCNCyclerion Therapeutics2.3332 of 5 stars$2.55+6.7%N/A-3.3%$8.51M$2.17M-3.4530Analyst Forecast Related Companies and Tools Related Companies Kiora Pharmaceuticals Alternatives Avalon GloboCare Alternatives TNF Pharmaceuticals Alternatives GeoVax Labs Alternatives Creative Medical Technology Alternatives Genprex Alternatives HCW Biologics Alternatives Briacell Therap Alternatives Qualigen Therapeutics Alternatives Cyclerion Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATXI) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avenue Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avenue Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
